C

Coya Therapeutics Inc
NASDAQ:COYA

Watchlist Manager
Coya Therapeutics Inc
NASDAQ:COYA
Watchlist
Price: 6.26 USD 0.64%
Market Cap: 104.7m USD
Have any thoughts about
Coya Therapeutics Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one COYA stock under the Base Case scenario is 6.42 USD. Compared to the current market price of 6.26 USD, Coya Therapeutics Inc is Undervalued by 2%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

COYA Relative Value
Base Case
6.42 USD
Undervaluation 2%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

28.7
P/S
P/S
Price to Sales
28.7
vs History
12
vs Industry
42
Median 3Y
10.6
Median 5Y
10.6
Industry
7.3
Forward
14.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.1
Industry
23.3
Forward
-5.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-6.9
Industry
19.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-6.9
Industry
22.6
More Details
3.2
P/B
P/B
Price to Book Value
3.2
vs History
33
vs Industry
30
Median 3Y
3
Median 5Y
3
Industry
2.7
More Details
18.6
EV/S
EV/S
Enterprise Value to Sales
18.6
vs History
9
vs Industry
42
Median 3Y
7.1
Median 5Y
7.1
Industry
7.6
Forward
9.3
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-4.7
Industry
4.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-4.6
Industry
4.8
Forward
-2.8
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-5.6
Industry
5.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-5.6
Industry
3.8
More Details
57.8
EV/IC
EV/IC
Enterprise Value to IC
57.8
vs History
24
vs Industry
14
Median 3Y
37.3
Median 5Y
37.3
Industry
5
More Details

Multiples Across Competitors

COYA Competitors Multiples
Coya Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Coya Therapeutics Inc
NASDAQ:COYA
104m USD 28.7 -6.2 -3.5 -3.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 841 650.5 -160 844.3 -195 316.3 -193 087.6
US
Abbvie Inc
NYSE:ABBV
336.7B USD 5.9 81 15.4 22.8
US
Amgen Inc
NASDAQ:AMGN
159.4B USD 4.7 26.9 14.4 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
141B USD 4.9 23.6 10.3 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.1B USD 11.1 -124.5 26.5 27.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 081.7 -531.2 -578.4 -563
AU
CSL Ltd
ASX:CSL
117B AUD 5 27.8 17.2 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.8B USD 4.2 13.3 11.9 13.3
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.5 -66.3 -59.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.8B USD 17.8 -155 -695.4 -348.5
P/E Multiple
Earnings Growth PEG
US
C
Coya Therapeutics Inc
NASDAQ:COYA
Average P/E: 34.5
Negative Multiple: -6.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 844.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.6
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -124.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.8
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -155 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
Coya Therapeutics Inc
NASDAQ:COYA
Average EV/EBITDA: 15.9
Negative Multiple: -3.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 316.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.9
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -695.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
Coya Therapeutics Inc
NASDAQ:COYA
Average EV/EBIT: 20.6
Negative Multiple: -3.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 087.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.8
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -348.5 N/A N/A

See Also

Summary
COYA intrinsic value, competitors valuation, and company profile.
DCF Valuation
COYA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
COYA stock valuation using valuation multiples.
Wall Street Estimates
COYA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
COYA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 266,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.